Addressing these challenges in ligand design through innovative strategies, structural optimization, and a deep understanding of PSMA biology is essential to enhance the affinity, specificity, and therapeutic potential of PSMA-targeted therapies for prostate cancer and other PSMA-expressing malignancies. The gene discussed is FOLH1; the disease is Familial prostate cancer.